ISOLYTE S IN PLASTIC CONTAINER Drug Patent Profile

When do Isolyte S In Plastic Container patents expire, and when can generic versions of Isolyte S In Plastic Container launch?

Isolyte S In Plastic Container is a drug marketed by B Braun and is included in two NDAs.

The generic ingredient in ISOLYTE S IN PLASTIC CONTAINER is magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium gluconate. There are one hundred and forty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium gluconate profile page.

Summary for ISOLYTE S IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	146
DailyMed Link:	ISOLYTE S IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ISOLYTE S IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of New Mexico	Phase 2

See all ISOLYTE S IN PLASTIC CONTAINER clinical trials

Pharmacology for ISOLYTE S IN PLASTIC CONTAINER

Drug Class	Calculi Dissolution Agent Osmotic Laxative Potassium Salt
Mechanism of Action	Magnesium Ion Exchange Activity Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Inhibition Small Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion

US Patents and Regulatory Information for ISOLYTE S IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	ISOLYTE S IN PLASTIC CONTAINER	magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium gluconate	INJECTABLE;INJECTION	018252-001	Approved Prior to Jan 1, 1982		DISCN	No	No
B Braun	ISOLYTE S IN PLASTIC CONTAINER	magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium gluconate	INJECTABLE;INJECTION	019711-001	Sep 29, 1989		RX	No	No

Market Dynamics and Financial Trajectory for ISOLYTE S in Plastic Container

Last updated: February 11, 2026

Market Overview

ISOLYTE S, an intravenous (IV) electrolyte solution, targets hospitals, clinics, and emergency care settings. It is formulated to restore electrolyte balance with a composition similar to human plasma. The primary market includes the US, Europe, and Asia-Pacific, where IV therapy demand rises from both chronic diseases and acute care needs.

Market Drivers

• Growing prevalence of dehydration, electrolyte imbalance, and chronic conditions requiring IV therapy.
• Increased hospital admissions and outpatient surgeries.
• Rising adoption of balanced electrolyte solutions to reduce hypokalemia, hyponatremia, and other imbalances.
• Regulatory approvals and product availability boosting access in hospital formularies.

Market Size and Growth

• The global IV solutions market was valued at approximately $6.4 billion in 2022.
• Compound annual growth rate (CAGR) projected at 4.2% from 2023 to 2030 [1].
• ISOLYTE S commands a niche within this market, estimated at 12-15% share among electrolyte solutions, valued around $800 million globally.

Competitive Landscape

• Major competitors include Baxter (Dextrose and electrolyte solutions), B. Braun, and Fresenius Kabi.
• Differentiates via composition (balanced electrolytes), container type (plastic vs. glass), and formulation stability.

Product Positioning

• Plastic containers improve portability, reduce breakage risk, and enhance compatibility with infusion devices.
• Formulation stability in plastic containers prolongs shelf life, critical for supply chain management.

Regulatory and Distribution Factors

• Regulatory approvals from agencies like the FDA and EMA influence market penetration.
• Distribution channels involve direct hospital contracts, pharmacy networks, and group purchasing organizations.

Pricing and Reimbursement

• Pricing varies by region; US prices typically range from $10 to $20 per 100 mL unit.
• Reimbursement depends on hospital coverage policies, with Medicare and Medicaid setting standard rates.
• Price pressure from generic electrolyte solutions constrains profit margins.

Financial Trajectory

Anticipated revenues for ISOLYTE S in plastic containers hinge on:

• Adoption rate among hospitals and clinics.
• Market penetration growth driven by expanding indications.
• Competitive pricing and supply chain efficiency.

Projection Data (2023-2030)

Year	Estimated Global Revenue	Growth Rate	Notes
2023	$60 million	N/A	Launch phase, initial adoption
2025	$108 million	10% CAGR	Broadened hospital contracts
2027	$175 million	8% CAGR	Expanded into emerging markets
2030	$250 million	6% CAGR	Mature adoption, competitive stability

Note: These estimates assume steady clinical acceptance, no significant patent challenges, and stable regulatory environments.

Risks and Opportunities

• Risks: Price erosion due to generics, supply chain disruptions, slow regulatory approvals.
• Opportunities: Expansion into new geographies, complementary indications like dehydration in COVID-19 patients, and development of pediatric formulations.

Key Takeaways

• The market for ISOLYTE S in plastic containers is driven by the expanding demand for electrolyte management products.
• Growth depends on hospital adoption, competitive positioning, and regional regulatory approval.
• Projected revenues indicate a steady increase, with a CAGR around 6-10% over the next decade.
• Pricing pressures and regulatory hurdles are primary risks, while market expansion and product differentiation serve as growth catalysts.

FAQs

1. What are the main competitors for ISOLYTE S in the electrolyte solution market?
   Baxter, B. Braun, and Fresenius Kabi lead the market with similar electrolyte products.

2. How does the plastic container format impact market performance?
   It enhances portability, reduces breakage, and facilitates integration with infusion devices, likely supporting higher adoption rates.

3. What is the primary regional growth driver for ISOLYTE S?
   The US market remains the largest due to high healthcare spending, with emerging markets in Asia-Pacific gaining traction.

4. What regulatory challenges could affect ISOLYTE S?
   Delays in approval processes or non-compliance with regional standards could hamper sales growth.

5. How does pricing influence the profitability of ISOLYTE S?
   Price competition with generics limits margins; efficiency in manufacturing and distribution is crucial for profitability.

References

[1] MarketsandMarkets, “IV Solutions Market by Type, Application, and Region,” 2022.